

Policies Repository



Policy Title Fluticasone Furoate (Veramyst®) Nasal Spray

Policy Number FS.CLIN.30

Application of Pharmacy Policy is determined by benefits and contracts. Benefits may vary based on product line, group or contract. Some medications may be subject to precertification, age, gender or quantity edits. Individual member benefits must be verified.

This Pharmacy Policy document describes the status of pharmaceutical information and/or technology at the time the document was developed. Since that time, new information relating to drug efficacy, interactions, contraindications, dosage, administration routes, safety or FDA approval may have changed. If the Medical/Pharmacy Reviewer is aware of any new information on the subject of this document, please provide it promptly to the Medical/Pharmacy Policy Department. This information may include new FDA approved indications, withdrawals or other FDA alerts. This type of information is relevant not only when considering whether this Policy should be updated, but also when applying it to current requests for coverage.

Members are advised to use participating pharmacies in order to receive the highest level of benefits.

Policy **Fluticasone furoate (Veramyst®)** nasal spray is indicated for the treatment of symptoms of seasonal and perennial allergic rhinitis in adults and children 2 years of age and older.

The use of fluticasone furoate (Veramyst®) requires prior authorization (ie, clinical pharmacy and/or Medical Director review).

Policy Description **Fluticasone furoate (Veramyst®)** nasal spray is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. The precise mechanism through which fluticasone furoate (Veramyst®) affects rhinitis symptoms is unknown, but corticosteroids have been shown to have a wide range of actions on multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (eg, histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation.

Policy Guideline Inclusion **Fluticasone furoate (Veramyst®)** is approved when there is documentation of a diagnosis of seasonal or perennial allergic rhinitis and **one** of the following:

- Documentation that the individual is 2 or 3 years of age, with documentation of trial and failure of or intolerance/contraindication/allergy to mometasone furoate monohydrate (Nasonex®) and triamcinolone acetonide (Nasacort AQ)

- Documentation that the individual is 4 years of age or older, with documentation of trial and failure of or intolerance/contraindication/allergy to fluticasone propionate containing nasal product and one of the following:
 - Mometasone furoate monohydrate (Nasonex®)
 - Triamcinolone acetonide (Nasacort® AQ)

Policy Guideline Exclusion

Fluticasone furoate (Veramyst®) is denied when **any** of the following exclusion criteria are present:

- No documentation of diagnosis of seasonal or perennial allergic rhinitis
- The individual is 2 or 3 years of age, with no documentation of trial and failure of or intolerance/contraindication/allergy to mometasone furoate monohydrate (Nasonex®) and triamcinolone acetonide (Nasacort AQ)
- The individual is 4 years of age or older, with no documentation of trial and failure of or intolerance/contraindication/allergy to fluticasone propionate containing nasal product and either mometasone furoate monohydrate (Nasonex®) or triamcinolone acetonide (Nasacort® AQ)
- The individual is younger than 2 years of age

Policy List of Applicable Drugs

Brand Name	Generic Name
Veramyst	fluticasone furoate

Dosing and Administration

Refer to the specific manufacturer's prescribing information for administration and dosage details for each specific agent.

Policy References

Facts & Comparisons. Veramyst®. [Facts & Comparisons Web site]. Available at: <http://online.factsandcomparisons.com> [via subscription only]. Accessed September 1, 2008.

Micromedex. Veramyst®. [Micromedex web site]. Available at: <http://www.micromedex.com> [via subscription only]. Accessed September 1, 2008.

Veramyst® [package insert]. Triangle Park, NC: GlaxoSmithKline, Inc.; 2007. Also available online at: http://us.gsk.com/products/assets/us_veramyst.pdf. Accessed October 16, 2008.

Policy Link to Related Policies

Printed

 01/06/2009 14:33:58

The Policy Bulletins on this web site were developed to assist Independence Blue Cross and its subsidiaries ("IBC") in administering the provisions of the respective benefit programs, and do not constitute a contract. If you are an IBC member, please refer to your specific benefit program for the terms, conditions, limitations and exclusions of your coverage. IBC does not provide health care

services, medical advice or treatment, or guarantee the outcome or results of any medical services/treatments. The facility and professional providers are responsible for providing medical advice and treatment. Facility and professional providers are independent contractors and are not employees or agents of IBC. If you have a specific medical condition, please consult with your doctor. IBC reserves the right at any time to change or update its Policy Bulletins. © 2008 Independence Blue Cross. All Rights Reserved. Current Procedural Terminology © 2008 American Medical Association. All Rights Reserved.

|